The primary objective of this study is to establish a control population to assess performance of an investigational diagnostic test targeting lung neoplasms.
Subjects will be participating in a lung cancer screening program at enrollment. Subjects will have a blood sample collected within 60 days of a low-dose CT scan (LDCT). Subjects with nodules present on the LDCT or subjects with a clean LDCT scheduled for a 12-month follow-up may have another blood draw at 12 months.
Study Type
OBSERVATIONAL
Enrollment
1,718
Subjects participating in the study will have blood sample collected at enrollment. . For any subjects scheduled for a 12 month follow-up, additional blood samples will be collected at 12 months from enrollment.
Biomarker Identification
Biomarkers under evaluation include differential methylation of nucleic acids and altered expression of proteins in blood to detect lung cancer
Time frame: 27 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Achieve Clinical Research
Birmingham, Alabama, United States
Phoenix Medical Group
Peoria, Arizona, United States
Highlands Oncology Group
Springdale, Arkansas, United States
NewportNativeMD, Inc.
Newport Beach, California, United States
Palmtree Clinical Research, Inc.
Palm Springs, California, United States
International Research Partners, LLC
Doral, Florida, United States
Clinical Trials of Florida, LLC
Miami, Florida, United States
Sarkis Clinical Trials
Ocala, Florida, United States
Sarasota Memorial Hospital
Sarasota, Florida, United States
Pasadena Center for Medical Research, Inc.
St. Petersburg, Florida, United States
...and 21 more locations